A taRNA vaccine candidate induces a specific immune response that protects mice against Chikungunya virus infections

The arthritogenic alphavirus, chikungunya virus (CHIKV), is now present in almost 100 countries worldwide. Further spread is very likely, which raises public health concerns. CHIKV infections cause fever and arthralgia, which can be debilitating and last for years. Here, we describe a CHIKV vaccine...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Christin Schmidt, Erik Haefner, Julia Gerbeth, Tim Beissert, Ugur Sahin, Mario Perkovic, Barbara S. Schnierle
Format: Artigo
Langue:Inglês
Publié: Elsevier 2022-06-01
Collection:Molecular Therapy: Nucleic Acids
Sujets:
MT: Delivery Strategies
chikungunya virus
RNA vaccine
protection
replicon
taRNA
Accès en ligne:http://www.sciencedirect.com/science/article/pii/S2162253122001135
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires